Business · 04/08/2023Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for PIFELTRO New Drug Application
Summary
The FDA has determined the regulatory review period for PIFELTRO, new drug application 210806, due to a patent extension application submitted to the USPTO, and is publishing this notice as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →